Key result
The Mitroflow aortic pericardial bioprosthesis demonstrated effective orifice areas ranging from 1.4 to 1.8 cm2 and mean gradients from 10.6 to 15.1 mmHg across 19 to 25 mm valve sizes.
Observational (n=55)
The Mitroflow aortic pericardial bioprosthesis demonstrates acceptable in vivo effective orifice areas across all valve sizes, which may help avoid prosthesis-patient mismatch in patients with a small aortic annulus.
Answers are grounded in this paper and cite their sources.
May aid small-annulus patients by limiting mismatch; extends observational hemodynamics but leaves outcome impact open.
BACKGROUND: Documentation of the hemodynamics of the Mitroflow aortic pericardial bioprosthesis has been incomplete. The aim of the study was to provide reference effective orifice areas for the implant calculation of effective orifice area indexes to avoid prosthesis-patient mismatch. METHODS: Echocardiograms were evaluated in 55 patients (39 females, 16 males), mean age 77.0 +/- 6.9 years (range 51-90 years). The mean time of the studies was 11.0 months. The prosthesis sizes and numbers evaluated were 19 mm (n = 13), 21 mm (n = 19), 23 mm (n = 13) and 25 mm (n = 10). RESULTS: Peak aortic velocities averaged from 2.2 to 2.7 m/sec, mean gradients from 10.6 to 15.1 mmHg, peak gradients from 20.7 to 29.7 mmHg, and effective orifice area (EOA) from 1.4 to 1.8 cm (2). When accounting for the subaortic velocity, mean gradients averaged from 7.5 to 10.0 mmHg, and peak gradients averaged 15.1 to 23.5 mmHg. The effective orifice area indexes ranged from 0.8 to 1.0 cm (2)/m (2). The mean postoperative left ventricular mass index was 101.6 gm/m (2). CONCLUSIONS: The IN VIVO effective orifice areas by valve size of the Mitroflow aortic pericardial bioprosthesis provide the opportunity of avoiding obstructive characteristics for all valve sizes, including optimizing the management of the small aortic annulus.
No takes yet. Share an insight, caveat, or question.
Jamieson et al. (2010) conducted an observational in Aortic valve replacement with Mitroflow bioprosthesis (n=55). Mitroflow aortic pericardial bioprosthesis was evaluated on Effective orifice area and transvalvular gradients. The Mitroflow aortic pericardial bioprosthesis demonstrated effective orifice areas ranging from 1.4 to 1.8 cm2 and mean gradients from 10.6 to 15.1 mmHg across 19 to 25 mm valve sizes.
Synapse has enriched 10 related papers. Consider them for comparative context: